

Rystiggo (rozanolixizumab-noli)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Rystiggo (rozanolixizumab-noli)	1
Summary	2
Definitions	2
Clinical Indications	3
Medical Necessity Criteria for Initial Clinical Review	3
Initial Indication-Specific Criteria	3
Generalized Myasthenia Gravis (gMG)	3
Medical Necessity Criteria for Subsequent Clinical Review	4
Generalized Myasthenia Gravis (gMG)	4
Experimental or Investigational or Unproven / Not Medically Necessary	5
Applicable Billing Codes	6
Appendix A	7
References	7
Clinical Guideline Revision / History Information	9

Summary

Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. It is caused by the production of autoantibodies that target components of the neuromuscular junction, such as the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK). The condition leads to a breakdown in communication between nerves and muscles, resulting in weakness and fatigue of voluntary muscles.

Symptoms of gMG can vary but commonly include weakness of the eye muscles (ocular myasthenia), drooping eyelids (ptosis), blurred or double vision (diplopia), changes in facial expressions, difficulty swallowing, and shortness of breath. The severity of gMG is often classified using the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification, which categorizes the disease into five main classes (I-V) based on signs, symptoms, and degree of impairment. This classification helps guide treatment decisions and assess disease progression.

Rystiggo (rozanolixizumab-noli), a neonatal Fc receptor blocker, is a prescription medicine indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR or anti-MuSK antibody positive. It is administered through weekly subcutaneous infusions and is designed to target the underlying autoimmune mechanisms of gMG. Management of gMG includes but is not limited to: surgical approaches, cholinesterase inhibitors (e.g., pyridostigmine), immunotherapy (e.g., corticosteroids, azathioprine, mycophenolate mofetil), and intravenous immune globulin. Those with anti-MuSK have been shown to be less responsive to cholinesterase inhibitors, and once started on corticosteroids, often find themselves steroid-dependent despite addition of other therapies. Rystiggo (rozanolixizumab-noli) is the first and only FDA-approved agent for anti-MuSK gMG.

Definitions

"Documentation" refers to written information, including but not limited to:

- Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses; or
- Prescription claims records, and/or prescription receipts to support prior trials of formulary alternatives.

"Generalized myasthenia gravis (gMG)" is a chronic autoimmune neuromuscular disorder characterized by fluctuating weakness of voluntary muscles.

"Anti-acetylcholine receptor (anti-AChR) antibodies" are autoantibodies directed against the nicotinic acetylcholine receptor found at the neuromuscular junction.

"Anti-muscle specific tyrosine kinase (anti-MuSK) antibodies" are autoantibodies directed against the muscle-specific tyrosine kinase protein.

"Cholinesterase inhibitors" refer to a class of drugs that prevent the breakdown of acetylcholine, a neurotransmitter which plays a major role in memory and muscle movement and contraction.

"Myasthenia Gravis Foundation of America (MGFA) Clinical Classification" is a system that categorizes disease severity into five main classes (I-V) with subclasses based on signs, symptoms, and degree of impairment.

"Myasthenia Gravis Activities of Daily Living (MG-ADL)" is an 8-item patient-reported questionnaire that assesses daily functions often impacted by myasthenia gravis. Total score ranges from 0 to 24, with a higher score indicating more disability. A positive change in the score indicates worsening and a negative change indicates improvement.

"Quantitative Myasthenia Gravis (QMG)" is a comprehensive 13-item scale specifically designed to accurately assess the severity of myasthenia gravis. It evaluates various aspects such as endurance, fatigability, and fluctuations in symptoms. The scale assigns scores ranging from 0 to 39, with higher scores indicating a more severe manifestation of the disease. A positive change in the score indicates worsening and a negative change indicates improvement.

"[s]" indicates state mandates may apply.

Clinical Indications

Medical Necessity Criteria for Initial Clinical Review

Initial Indication-Specific Criteria

Generalized Myasthenia Gravis (gMG)

The Plan considers Rystiggo (rozanolixizumab-noli) medically necessary when ALL of the following criteria are met:

1. Prescribed by or in consultation with a neurologist or neuromuscular disease specialist; *AND*
2. The member is 18 years of age or older; *AND*
3. The member has a confirmed diagnosis of generalized myasthenia gravis (gMG) *AND* documentation of ALL of the following:
 - a. Positive serologic test for anti-acetylcholine receptor (anti-AChR) OR anti-muscle specific tyrosine kinase (anti-MuSK) antibodies; *and*
 - b. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IVa (see [Appendix A](#), Table 1); *and*
 - c. Baseline Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score of at least 3 (with at least 3 points from non-ocular symptoms); *AND*
4. The member meets ONE of the following:

- a. IF anti-AChR antibody positive, the member is unable to use, or has tried and failed TWO (2) of the following, each from a different class^[5]:
 - i. Cholinesterase inhibitor (e.g., pyridostigmine); *and/or*
 - ii. Corticosteroid (e.g., prednisone) or inability to taper steroids below a reasonably acceptable level without return of symptoms; *and/or*
 - iii. Non-steroidal immunosuppressive therapy (e.g., azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate, tacrolimus); *or*
- b. IF anti-MuSK antibody positive, the member is unable to use, or has tried and failed ONE of the following^[5]:
 - i. TWO (2) immunosuppressive therapies (e.g., azathioprine, corticosteroid, cyclosporine, cyclophosphamide, methotrexate, mycophenolate, tacrolimus); *or*
 - ii. ONE immunosuppressive therapy and intravenous immunoglobulin (IVIG); *AND*
- 5. The drug will not be used concomitantly with other immunomodulatory biologic therapies for generalized myasthenia gravis (e.g., efgartigimod alfa, inebilizumab, nipocalimab, rituximab, ravulizumab, zilucoplan, etc.); *AND*
- 6. Treatment cycles are no more frequent than every 63 days from the start of the previous treatment cycle; *AND*
- 7. Rystiggo (rozanolixizumab-noli) is being prescribed at a dose and frequency that is within FDA approved labeling *OR* is supported by compendia or evidence-based published dosing guidelines for the requested indication.

Note: The recommended dosage is administered as a subcutaneous infusion once weekly for 6 weeks. Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 63 days from the start of the previous treatment cycle has not been established.

If the above prior authorization criteria are met, the requested product will be authorized for up to 6-months.^[5]

Continued Care

Medical Necessity Criteria for Subsequent Clinical Review

Generalized Myasthenia Gravis (gMG)

The Plan considers Rystiggo (rozanolixizumab-noli) medically necessary when ALL of the following criteria are met:

- 1. Prescribed by or in consultation with a neurologist or neuromuscular disease specialist; *AND*
- 2. Documentation of positive clinical response to therapy, such as ONE (1) of the following:
 - a. Improvement in Myasthenia Gravis-Activities of Daily Living (MG-ADL), MG Manual Muscle Test (MMT), MG-Composite, *OR* Quantitative Myasthenia Gravis (QMG) score from baseline; *or*
 - b. Achievement of minimal symptom expression or pharmacological remission; *or*

- c. Lack of relapses or reduced frequency/severity of relapses compared to baseline; *AND*
3. Ongoing therapy is required to maintain disease stability and control; *AND*
4. There is no unacceptable toxicity or adverse reaction to therapy, such as:
 - a. Serious infections (e.g. serious respiratory or urinary tract infections); *and/or*
 - b. Severe hypersensitivity reactions; *and/or*
 - c. Severe immunosuppression; *and/or*
 - d. Other intolerable side effects or reactions; *AND*
5. Will not be used concomitantly with other immunomodulatory biologic therapies for generalized myasthenia gravis (e.g., efgartigimod alfa, inebilizumab, nipocalimab, rituximab, rozanolixizumab, ravulizumab, zilucoplan, etc.); *AND*
6. Treatment cycles are no more frequent than every 63 days from the start of the previous treatment cycle; *AND*
7. Rystiggo (rozanolixizumab-noli) is being prescribed at a dose and frequency that is within FDA approved labeling OR is supported by compendia or evidence-based published dosing guidelines for the requested indication.

Note: The recommended dosage is administered as a subcutaneous infusion once weekly for 6 weeks. Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 63 days from the start of the previous treatment cycle has not been established.

If the above reauthorization criteria are met, the requested product will be authorized for up to 6-months.^[s]

Experimental or Investigational or Unproven / Not Medically Necessary^[s]

Rystiggo (rozanolixizumab-noli) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary.

Non-covered indications include, but are not limited to, the following:

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Only one small (n=34) randomized, subject-blinded study evaluated Rystiggo (rozanolixizumab-noli) versus placebo for CIDP, which failed to meet the primary outcome of change from baseline to day 85 inflammatory Rasch-built Overall Disability Scale score.
- Fibromyalgia. Only one small (n=63) proof-of-concept study has been conducted evaluating Rystiggo (rozanolixizumab-noli) versus placebo (NCT05643794) for the management of fibromyalgia. This study failed to meet the primary outcome of improvement of brief pain inventory short form (BPI-SF) at week 12.
- Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis. Only one terminated study (NCT04875975) has been identified evaluating Rystiggo (rozanolixizumab-noli) for this indication. No high quality studies have evaluated the safety and efficacy of Rystiggo (rozanolixizumab-noli) for this indication.

- Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD). No high quality studies have evaluated the safety and efficacy of Rystiggo (rozanolixizumab-noli) for this indication.
- Primary Immune Thrombocytopenia (ITP). Clinical trials studying Rystiggo (rozanolixizumab-noli) have failed to show significant improvement in serum markers of ITP, or have been terminated early.
- Thrombocytopenia. No high quality studies have evaluated the safety and efficacy of Rystiggo (rozanolixizumab-noli) for thrombocytopenia.

Applicable Billing Codes

Table 1	
CPT/HCPCS Codes for myasthenia gravis considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
96369	Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); initial, up to 1 hour, including pump set-up and establishment of subcutaneous infusion site(s)
96371	Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); additional pump set-up with establishment of new subcutaneous infusion site(s) (List separately in addition to code for primary procedure)
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic
J9333	Injection, rozanolixizumab-noli, 1 mg

Table 2	
ICD-10 codes considered medically necessary for myasthenia gravis with Table 1 (CPT/HCPCS) codes if criteria are met:	
<i>Code</i>	<i>Description</i>
G70.0	Myasthenia gravis
G70.00	Myasthenia gravis without (acute) exacerbation
G70.01	Myasthenia gravis with (acute) exacerbation
G70.2	Congenital and developmental myasthenia

Appendix A

Table 3: Summary of Myasthenia Gravis Foundation of America (MGFA) Disease Clinical Classification

<i>Class</i>	<i>Description</i>
I	Ocular muscle weakness; All other muscles - normal strength
II	Mild generalized weakness
IIa	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
IIb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
III	Moderate generalized weakness
IIIa	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
IIIb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
IV	Severe generalized weakness
IVa	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
IVb	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
V	Intubation, with or without ventilation; Not for routine postoperative care

NOTE: The preceding table summarizes key aspects of the Myasthenia Gravis Foundation of America (MGFA) Disease Classifications. This is provided only for quick reference. For the exact definitions and details on the MGFA Disease Classifications, please refer to the original MGFA Classification document available at <https://myasthenia.org/Portals/0/MGFA%20Classification.pdf>.

References

1. Barnett-Tapia C, Cortés Vicente E, et al. Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study. *J Neurol*. 2025 Nov 8;272(12):752. doi: 10.1007/s00415-025-13480-8.
2. Bril V, Antozzi C, Berkowicz T, et al. Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study. *J Neurol*. 2025 Oct 11;272(10):686. doi: 10.1007/s00415-025-13420-6.
3. Bril V, Benatar M, Andersen H, MG0002 Investigator Study Group, et al. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis A Phase 2 Randomized Control Trial. *Neurology* Feb 2021, 96 (6) e853-e865; DOI: 10.1212/WNL.0000000000011108.
4. Bril V, Druzdź A, Grosskreutz J, and MG0003 study team. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. *Lancet Neurol*. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. PMID: 37059507. <https://pubmed.ncbi.nlm.nih.gov/37059507>

5. Bril V, Druzd A, Grosskreutz J, et al. Long-term Efficacy and Safety of Symptom-driven Cyclic Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis: A Pooled Analysis of a Phase 3 Study and Two Open-label Extension Studies (P1-5.012). *Neurology* Apr 2023, 100 (17 Supplement 2) 3747; DOI: 10.1212/WNL.0000000000203497
6. Bril V, Drużdż A, Grosskreutz J, et al. Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions. *J Neuromuscul Dis.* 2025 Mar;12(2):218-230. doi: 10.1177/22143602241305511. Epub 2025 Mar 4.
7. Cooper N, Bussel JB, Kaźmierczak M, et al. Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension. *Br J Haematol.* 2025 Feb;206(2):675-688. doi: 10.1111/bjh.19858. Epub 2024 Nov 18.
8. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. *J Peripher Nerv Syst.* 2022 Mar;27(1):94. doi: 10.1111/jns.12479. Epub 2022 Jan 10. Erratum for: *J Peripher Nerv Syst.* 2021 Sep;26(3):242-268. doi: 10.1111/jns.12455.
9. Farrugia ME et al: A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. *Front Neurol.* 11:604, 2020
10. Gronseth GS et al: Practice advisory: thymectomy for myasthenia gravis (practice parameter update): report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* 94(16):705-9, 2020
11. Guidon AC, Muppidi S, Nowak RJ, et al. Telemedicine visits in myasthenia gravis: expert guidance and the Myasthenia Gravis Core Exam (MG-CE). *Muscle Nerve* 2021; 64:270-276.
12. Habib AA, Drużdż A, Grosskreutz J, et al. Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension. *J Neuromuscul Dis.* 2025 Mar;12(2):231-243. doi: 10.1177/22143602241308181. Epub 2025 Mar 4.
13. Habib AA, Sacconi S, Antonini G, et al. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. *Ther Adv Neurol Disord.* 2024 Sep 12:17:17562864241273036. doi:10.1177/17562864241273036. eCollection 2024.
14. Jaretzki A 3rd et al: Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. *Neurology.* 55(1):16-23, 2000
15. Jayam-Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. *Autoimmune Dis.* 2012;2012:874680. doi:10.1155/2012/874680.
16. Kaminski HJ, Antozzi C, Habib AA, et al. Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO. *Eur J Neurol.* 2025 Aug;32(8):e70231. doi: 10.1111/ene.70231.
17. Li J, Wu X, Chu T, et al. The efficacy and safety of FcRN inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. *J Neurol.* 2024 May; 271(5):2298-2308. doi:10.1007/s00415-024012247-x. Epub 2024 Mar 3.
18. Ma Y, Nie X, Zhu G, et al. The efficacy and safety of different targeted drugs for the treatment of generalized Myasthenia Gravis: a systematic review and bayesian network meta-analysis. *CNS Drugs.* 2024 Feb;38(2):93-104. doi:10.1007/s40263-024-01062-7. Epub 2024 Feb 1.
19. Narayanaswami P, Sanders D, Wolfe G, Benatar M, et al. International consensus guidance for management of myasthenia gravis, 2020 update. *Neurology* 2021;96:114-122. doi:10.1212/WNL.0000000000001124.
20. Querol L, De Sèze J, Dysgaard T, et al. Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension

- study. *J Neurol Neurosurg Psychiatry*. 2024 Aug 16;95(9):845-854. doi: 10.1136/jnnp-2023-333112.
21. Robak T, Kaźmierczak M, Jarque I, et al. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. *Blood Adv*. 2020 Sep 8;4(17):4136-4146. doi: 10.1182/bloodadvances.2020002003.
 22. Rystiggo (rozanolixizumab) [prescribing information]. Smyrna, GA: UCB Inc; December 2025.
 23. Sacca F, Pane C, Espinosa PE, et al. Efficacy and innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. *Eur J Neurol*. 2023 Dec;30(12):3854-3867. doi:10.1111/ene.15872. Epub 2023 May 30.
 24. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. *Neurology*. 2016;87(4):419-425. doi:10.1212/WNL.0000000000002790
 25. Smith AG, Wolfe GI, Habib AI, et al. Risk-benefit analysis of novel treatments for patients with generalized myasthenia gravis. *Adv Ther*. 2024 Dec; 41(12):4628-4647. doi:10.1007/s12325-024-03014-5. Epub 2024 Oct 29.
 26. Sussman J et al: The Association of British Neurologists' myasthenia gravis guidelines. *Ann N Y Acad Sci*. 1412(1):166-9, 2018
 27. Sussman J, Farrugia ME, Maddison P, et al. Myasthenia gravis: Association of British Neurologists' management guidelines. *Pract Neurol* 2015; 15: 199-206.
 28. Tavee J, Brannagan TH 3rd, Lenihan MW, et al. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. *Muscle Nerve*. 2023 Oct;68(4):356-374. doi: 10.1002/mus.27922. Epub 2023 Jul 11.
 29. Zhong H, Li Z, Li X, et al. Initiation response, maximized therapeutic efficacy and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis. *Front Neurol*. 2024 Oct 28;15:1479685. doi:10.3389/fneur.2024.1479685. eCollection 2024.

Clinical Guideline Revision / History Information

Original Date: 1/26/2024

Reviewed/Revised: 7/1/2025, 05/01/2026, 09/01/2026